Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
J Heart Lung Transplant. 2021 May;40(5):351-358. doi: 10.1016/j.healun.2021.01.1391. Epub 2021 Jan 23.
Previous studies have reported similarities in long-term outcomes following lung transplantation for connective tissue disease-associated interstitial lung disease (CTD-ILD) and idiopathic pulmonary fibrosis (IPF). However, it is unknown whether CTD-ILD patients are at increased risk of primary graft dysfunction (PGD), delays in extubation, or longer index hospitalizations following transplant compared to IPF patients.
We performed a multicenter retrospective cohort study of CTD-ILD and IPF patients enrolled in the Lung Transplant Outcomes Group registry who underwent lung transplantation between 2012 and 2018. We utilized mixed effects logistic regression and stratified Cox proportional hazards regression to determine whether CTD-ILD was independently associated with increased risk for grade 3 PGD or delays in post-transplant extubation and hospital discharge compared to IPF.
A total of 32.7% (33/101) of patients with CTD-ILD and 28.9% (145/501) of patients with IPF developed grade 3 PGD 48-72 hours after transplant. There were no significant differences in odds of grade 3 PGD among patients with CTD-ILD compared to those with IPF (adjusted OR 1.12, 95% CI 0.64-1.97, p = 0.69), nor was CTD-ILD independently associated with a longer post-transplant time to extubation (adjusted HR for first extubation 0.87, 95% CI 0.66-1.13, p = 0.30). However, CTD-ILD was independently associated with a longer post-transplant hospital length of stay (median 23 days [IQR 14-35 days] vs17 days [IQR 12-28 days], adjusted HR for hospital discharge 0.68, 95% CI 0.51-0.90, p = 0.008).
Patients with CTD-ILD experienced significantly longer postoperative hospitalizations compared to IPF patients without an increased risk of grade 3 PGD.
先前的研究报告称,结缔组织病相关间质性肺疾病(CTD-ILD)和特发性肺纤维化(IPF)患者肺移植后的长期结果存在相似性。然而,与 IPF 患者相比,CTD-ILD 患者在移植后是否更有可能发生原发性移植物功能障碍(PGD)、拔管延迟或住院时间延长,目前尚不清楚。
我们对 2012 年至 2018 年间在肺移植结局组登记处接受肺移植的 CTD-ILD 和 IPF 患者进行了一项多中心回顾性队列研究。我们利用混合效应逻辑回归和分层 Cox 比例风险回归来确定 CTD-ILD 是否与 IPF 相比,与 PGD 3 级、移植后拔管和出院延迟的风险增加独立相关。
共有 32.7%(33/101)的 CTD-ILD 患者和 28.9%(145/501)的 IPF 患者在移植后 48-72 小时发生 3 级 PGD。与 IPF 患者相比,CTD-ILD 患者发生 3 级 PGD 的几率无显著差异(校正比值比 1.12,95%CI0.64-1.97,p=0.69),CTD-ILD 也与移植后拔管时间延长无关(首次拔管的校正 HR0.87,95%CI0.66-1.13,p=0.30)。然而,CTD-ILD 与移植后住院时间延长独立相关(中位数 23 天[IQR14-35 天]比 17 天[IQR12-28 天],校正 HR 用于出院 0.68,95%CI0.51-0.90,p=0.008)。
与无 CTD-ILD 的 IPF 患者相比,CTD-ILD 患者术后住院时间明显延长,但 3 级 PGD 的风险并未增加。